Earnings summaries and quarterly performance for BriaCell Therapeutics.
Research analysts covering BriaCell Therapeutics.
Recent press releases and 8-K filings for BCTX.
BriaCell Therapeutics Releases New Images Highlighting Resolution of Metastatic Breast Cancer Lesions
BCTX
New Projects/Investments
- BriaCell Therapeutics Corp. released new images on January 28, 2026, highlighting the resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvement.
- The images confirm clinical responses and verify the BriaCell treatment's ability to activate CD8+ cytotoxic T cells and induce their infiltration into cancerous tumors.
- No Bria-IMT related discontinuations have been reported to date in the Phase 2 study, which enrolled 54 heavily pre-treated metastatic breast cancer patients.
- The Bria-IMT regimen continues under Fast Track Designation from the US FDA.
Jan 28, 2026, 12:30 PM
BriaCell Therapeutics Announces Positive Phase 2 Survival Data for Metastatic Breast Cancer
BCTX
New Projects/Investments
- BriaCell Therapeutics announced positive Phase 2 survival data for its Bria-IMT regimen in metastatic breast cancer patients, with 9 of 25 patients treated since 2022 remaining alive for over 18-47 months.
- The Bria-IMT regimen, which holds Fast Track Designation from the US FDA, has reported no Bria-IMT™ related discontinuations to date.
- For patients treated post-2022 with the Phase 3 formulation, the median overall survival was 15.6 months, with 52% 1-year survival and 32% 2-year survival, significantly exceeding benchmarks reported for standard of care therapies.
- BriaCell plans to confirm these findings in an ongoing pivotal Phase 3 study with overall survival as its primary endpoint.
Jan 27, 2026, 12:30 PM
BriaCell Therapeutics Prices $30 Million Public Offering
BCTX
New Projects/Investments
- BriaCell Therapeutics Corp. announced the pricing of a public offering of 5,366,726 units at $5.59 per unit, anticipating gross proceeds of approximately $30 million.
- Each unit consists of one common share (or pre-funded warrant) and one warrant, with the warrants expected to commence trading on the Nasdaq Capital Market under the symbol "BCTXL" on January 14, 2026.
- The warrants are immediately exercisable at $6.93 per share and will expire five years from the date of issuance.
- The offering is expected to close on January 15, 2026, with net proceeds allocated for working capital requirements, general corporate purposes, and the advancement of the Company’s business objectives.
Jan 15, 2026, 9:15 PM
BriaCell Therapeutics Closes US$30 Million Public Offering
BCTX
- BriaCell Therapeutics Corp. announced the closing of its best-efforts public offering on January 15, 2026.
- The offering generated gross proceeds of approximately US$30 million from the sale of 5,366,726 units at US$5.59 per unit.
- Each unit included one common share (or pre-funded warrant) and one warrant, with the warrants trading under "BCTXL" and exercisable at US$6.93 per share.
- The company intends to use the net proceeds for working capital, general corporate purposes, and advancing business objectives.
Jan 15, 2026, 9:05 PM
BriaCell Therapeutics Announces Pricing of Public Offering
BCTX
- BriaCell Therapeutics, a clinical-stage biotechnology company, announced the pricing of a best-efforts public offering.
- The offering includes 5,366,726 units priced at $5.59 per unit, aiming for approximately $30 million in gross proceeds.
- Each unit comprises one common share (or pre-funded warrant) and one warrant. The warrants are immediately exercisable at $6.93 per share, expire in five years, and are approved for listing on the Nasdaq Capital Market under the symbol "BCTXL".
- The offering is expected to close on January 15, 2026, with net proceeds intended for working capital, general corporate purposes, and the advancement of business objectives.
Jan 14, 2026, 2:00 AM
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS Patient
BCTX
New Projects/Investments
- BriaCell Therapeutics announced the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer treated with its Bria-OTS personalized off-the-shelf immunotherapy.
- The complete response was initially observed at 2 months and confirmed at 4, 6, and 11 months in a 78-year-old patient who had previously failed multiple treatments.
- The patient received 17 cycles of Bria-OTS with no treatment limiting toxicities reported.
- The Phase 1 dose escalation portion of the Bria-OTS study is complete, and the Phase 2a portion, evaluating combination therapy with an immune checkpoint inhibitor, is now underway.
Jan 13, 2026, 12:30 PM
BriaCell Therapeutics Presents Positive Phase 3 Bria-ABC Study Data
BCTX
New Projects/Investments
- BriaCell Therapeutics Corp. presented positive data from its Phase 3 Bria-ABC study at the 2025 San Antonio Breast Cancer Symposium, demonstrating that biomarkers may predict clinical responses in metastatic breast cancer patients treated with the Bria-IMT regimen plus checkpoint inhibitors.
- An interim analysis of 116 patients showed favorable progression-free survival of 3.7 months in HR+/HER2- disease and 3.9 months in HER2-Low disease, with patients exhibiting a favorable Neutrophil-to-Lymphocyte Ratio achieving a median PFS of 4.4 months.
- BriaCell's Phase 2 data indicated a median overall survival of 11.3 months in DTH-positive patients and a 100% clinical benefit rate in evaluable CNS metastasis patients, with the Bria-IMT regimen being well tolerated.
Jan 7, 2026, 3:32 PM
BriaCell Therapeutics Presents Positive Phase 2 and Phase 3 Clinical Data at SABCS® 2025
BCTX
- BriaCell Therapeutics presented positive Phase 2 survival and Phase 3 biomarker data for its Bria-IMT regimen at the 2025 San Antonio Breast Cancer Symposium (SABCS®).
- The Bria-IMT regimen demonstrated a favorable safety profile in the Phase 3 study, with no treatment-related discontinuations due to adverse events.
- Maturing Phase 2 data showed a significantly higher median overall survival of 11.3 months in DTH+ patients compared to 4.7 months in DTH- patients.
- Biomarkers, including Neutrophil-to-Lymphocyte Ratio (NLR) and Th1 biased cytokines, are showing promise in predicting clinical responses and survival in both Phase 2 and Phase 3 studies.
- The Bria-IMT regimen achieved a 75% overall clinical benefit rate in evaluable patients with CNS metastasis.
Dec 10, 2025, 12:30 PM
BriaCell Therapeutics Provides Update on Phase 3 Patient Enrollment and Data Readout Timeline
BCTX
New Projects/Investments
Guidance Update
- BriaCell Therapeutics' pivotal Phase 3 study for metastatic breast cancer has screened over 230 patients and enrolled over 160 patients, with enrollment exceeding expectations.
- The company anticipates a topline interim data readout in 1H2026 for its Phase 3 study.
- The Bria-IMT combination regimen being evaluated in the Phase 3 study holds FDA Fast Track designation.
- Interim data analysis will be conducted once 144 patient events (deaths) occur, with positive results potentially leading to full approval and marketing authorization of Bria-IMT™.
Dec 9, 2025, 12:30 PM
Bicara Therapeutics Presents Preliminary Phase 1b Data for Ficerafusp Alfa and Targets Optimal Dose Declaration in Q1 2026
BCTX
New Projects/Investments
Guidance Update
- Bicara Therapeutics (Nasdaq: BCAX) presented preliminary Phase 1b data for 750 mg of ficerafusp alfa weekly in combination with pembrolizumab for first-line HPV-negative recurrent/metastatic HNSCC, demonstrating a 57% confirmed overall response rate and a consistent safety profile.
- New biomarker data suggests that a 1500mg dose of ficerafusp alfa leads to greater TGF-β inhibition and deeper clinical responses, with a median depth of response of 82% compared to 63% for the 750mg dose.
- The company is on track to declare the optimal biologic dose for its pivotal FORTIFI-HN01 study in the first quarter of 2026.
Dec 6, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more